Tovinontrine is under clinical development by Cardurion Pharmaceuticals and currently in Phase II for Systolic Heart Failure. According to GlobalData, Phase II drugs for Systolic Heart Failure have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tovinontrine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tovinontrine overview

Tovinontrine (IMR-687) is under development for the treatment of preserved ejection fraction (HFpEF) also referred to as diastolic heart failure and systolic heart failure (reduced ejection fraction). The drug candidate is administered through oral route in the form of tablets. It acts by targeting phosphodiesterase 9 (PDE9).

The drug candidate was under development for the treatment of sickle cell disease and beta thalassemia.

Cardurion Pharmaceuticals overview

Cardurion Pharmaceuticals is a biopharmaceutical company that develops drugs to address the unmet needs of people suffering from heart diseases. Its drug pipeline portfolio includes phosphodiesterase-9 (PDE9) inhibition and calcium–calmodulin-dependent protein kinase II (CaMKII) inhibition. Cardurion is developing drugs to treat cardiomyopathy, catecholaminergic polymorphic ventricular tachycardia (CPVT), arrhythmias, heart failure and other cardiac disorders. Cardurion Pharmaceuticals is headquartered in Burlington, Massachusetts, the US.

For a complete picture of Tovinontrine’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.